DoD Melanoma Research Program anticipated funding opportunities for FY23

Remote telemedicine tool found highly accurate in diagnosing melanoma

Collecting images of suspicious-looking skin growths and sending them off-site for specialists to analyze is as accurate in identifying skin cancers as having a dermatologist examine them in person, a new study shows.

November 22, 2024

Vol.50 No.44

Clinical Roundup

UVA Health tests focused ultrasound to increase immune response in melanoma

A research team at UVA Health is testing the ability of focused ultrasound to increase the immune response to immunotherapy in melanoma. UVA’s work with focused ultrasound already has led to life-changing new treatments for Parkinson’s disease and essential tremor and pushed the technology to the forefront of medical research.

November 22, 2024

Vol.50 No.44

In Brief

Qure.ai completes $65M Series D funding round

Qure.ai has announced the completion of a $65 million Series D funding round. The investment will expedite expansion into the U.S. market and other countries, increase investment in foundational AI models, and enable complementary med-tech company acquisitions.

October 04, 2024

Vol.50 No.37

In Brief

Roger Lo awarded $2M NIH grant to study melanoma treatment resistance

Roger Lo, professor of medicine, dermatology, and molecular and medical pharmacology and investigator at the UCLA Health Jonsson Comprehensive Cancer Center, was awarded a $2 million grant from NIH to investigate innovative strategies to prevent drug resistance in melanoma treatment and improve the effectiveness of MAPK inhibitors, a common treatment for patients with melanomas that carry the BRAFV600 mutation.

September 27, 2024

Vol.50 No.36

Regulatory News

Melanoma investigators invite FDA to publicly discuss approval endpoints and crossover design
The agency accepts the invitation

A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.

Group chairs propose funding strategy to jump-start correlative studies

The National Academy of Medicine recognized the value of correlative science in publicly funded clinical trials in 2010, recommending “the incorporation of innovative science into cancer clinical trials through the support and use of biorepositories.”

September 20, 2024

Vol.50 No.35

By Peter J. O'Dwyer

DoD Melanoma Research Program anticipated funding opportunities for FY23

YOU MAY BE INTERESTED IN

Remote telemedicine tool found highly accurate in diagnosing melanoma

UVA Health tests focused ultrasound to increase immune response in melanoma

Qure.ai completes $65M Series D funding round

Roger Lo awarded $2M NIH grant to study melanoma treatment resistance

Melanoma investigators invite FDA to publicly discuss approval endpoints and crossover design
The agency accepts the invitation

Group chairs propose funding strategy to jump-start correlative studies

Renew today!

Subscriber content

Never miss an issue!

Login

DoD Melanoma Research Program anticipated funding opportunities for FY23

YOU MAY BE INTERESTED IN

Remote telemedicine tool found highly accurate in diagnosing melanoma

UVA Health tests focused ultrasound to increase immune response in melanoma

Qure.ai completes $65M Series D funding round

Roger Lo awarded $2M NIH grant to study melanoma treatment resistance

Melanoma investigators invite FDA to publicly discuss approval endpoints and crossover designThe agency accepts the invitation

Group chairs propose funding strategy to jump-start correlative studies

Never miss an issue!

Login

Melanoma investigators invite FDA to publicly discuss approval endpoints and crossover design
The agency accepts the invitation